Osteopetrosis Clinical Trial
OBJECTIVES: I. Compare the rate of treatment failure in osteopetrosis patients receiving
interferon gamma in combination with calcitriol to the rate of treatment failure in patients
receiving calcitriol alone.
II. Compare the number of adverse events or clinical manifestations of disease progression
occurring in these patients.
III. Assess the effects of interferon gamma on hematopoiesis, cranial nerve function, and
rate of infection in these patients.
PROTOCOL OUTLINE: This is a randomized, placebo controlled, open label study. Patients are
randomized to one of two arms (interferon gamma in combination with calcitriol or calcitriol
alone).
Arm I: Patients receive calcitriol once daily. Interferon gamma is administered by
subcutaneous injection three times a week.
Arm II: Patients receive calcitriol once daily. Patients may continue treatment in the
absence of toxicity and disease progression. If disease progression is diagnosed in the
control group, patients will then receive interferon gamma in combination with calcitriol.
Patients are followed every 4 weeks.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01087398 -
Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis
|
Phase 2/Phase 3 | |
Terminated |
NCT00638820 -
Reduced Intensity AlloTransplant For Osteopetrosis
|
Phase 2 | |
Recruiting |
NCT01019876 -
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
|
Phase 2/Phase 3 | |
Terminated |
NCT00145587 -
Stem Cell Transplantation for Children Affected With Osteopetrosis
|
N/A | |
Completed |
NCT01199094 -
Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5
|
N/A | |
Completed |
NCT00043329 -
Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis
|
Phase 4 | |
Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
Completed |
NCT02666768 -
ACTIMMUNE in Intermediate Osteopetrosis
|
Phase 2 | |
Terminated |
NCT00145886 -
rhPTH Therapy for Low Turnover Bone Fragility
|
Phase 1 | |
Terminated |
NCT00968864 -
T-cell Depleted Alternative Donor Transplantation
|
Phase 2 | |
Completed |
NCT00730314 -
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03301168 -
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
|
Phase 1/Phase 2 | |
Terminated |
NCT02065869 -
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
|
Phase 1/Phase 2 | |
No longer available |
NCT01200017 -
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
|